US 11,377,636 B2Granted

Endogenous retrovirus transcription as a marker for primate naive pluripotent stem cells

AssigneesMax-DelbrüCk-Centrum FüR Molekulare Medizin In Der Helmholtz-Gemeinschaft, University of Bath

InventorsJichang Wang, Zsuzsanna Izsvák, Laurence Daniel Hurst

Life of this patent

Estimating the term…

Loading patent…

Abstract

An in vitro method for identifying, isolating and/or enriching primate naive pluripotent stem cells, the method including analyzing transcription of a type 7 long terminal repeat (LTR7) nucleic acid sequence of a type H human endogenous retrovirus (HERVH) (LTR7/HERVH-associated transcription), and identifying, isolating and/or enriching primate naive pluripotent stem cells based on LTR7/HERVH-associated transcription, wherein LTR7/HERVH-associated transcription is a marker for primate naive pluripotent stem cells. An isolated in vitro population of primate naive pluripotent stem cells is obtained by the method, wherein in the cells LTR7/HERVH-associated transcription is elevated in comparison to control cells, wherein control cells are primed pluripotent stem cells or differentiated cells.

Claims13

Dependent claims

An in vitro method for identifying, isolating and/or enriching primate naïve pluripotent stem cells in a stem cell population, the method comprising:

analyzing transcription of a type 7 long terminal repeat (LTR7) nucleic acid sequence of a type H human endogenous retrovirus (HERVH) (LTR7/HERVH-associated transcription) by measuring RNA levels of transcripts of the type 7 long terminal repeat (LTR7) nucleic acid sequence of the type H human endogenous retrovirus (HERVH) in cells of a stem cell population, and
identifying, isolating and/or enriching primate naïve pluripotent stem cells based on LTR7/HERVH-associated transcription, wherein naïve pluripotent stem cells are identified, isolated and/or enriched, in which LTR7/HERVH-associated transcription is elevated in comparison to control cells, wherein control cells are primed pluripotent stem cells or differentiated cells.

Dependencies are inferred from the claim text.

Facts

Application: 16/563,089Filed 6 Sep 2019 · continuation
Priority: DE 10 2014 114 558.57 Oct 2014
Published: US 2020/0063096 A127 Feb 2020
Granted: 5 Jul 2022
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C12N 5/0606
Embryonic cells ; Embryoid bodies: pluripotent embryonic cells, e.g. embryonic stem cells [ES]
C12N 5/0696
Vertebrate cells: artificially induced pluripotent stem cells, e.g. iPS
C12N 2500/90
Specific components of cell culture medium: serum-free medium, which may still contain naturally-sourced components
C12N 2500/98
Specific components of cell culture medium: xeno-free medium and culture conditions

Family

PCT/EP2015/073144Parent of this continuation · filed 7 Oct 2015
US 2020/0063096 A1Pre-grant publication · published 27 Feb 2020
Application15/517,904Parent of this continuation
US 2017/0313978 A1Published application
US 11,377,636 B2This patent

From the US filing history. Foreign family members aren’t listed.